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Abstract
Levamisole, an agent acting upon depressed cellular immunity, enhancing and normalizing
it and consequently showing antitumor activity in the cancer-bearing body, was administered to
patients with gastrointestinal cancer at a daily dose of 150 mg for three consecutive days every
other week, starting as a rule, three days before operation. The patients were evaluated for survival.
Of the 143 patients (66 with curative resection, 40 with noncurative resection and 37 without
resection) who received levamisole therapy for one month or more, 57 survived postoperatively
six months and of 44 treated 37 survived one year. In this study, 185 patients with gastrointestinal
cancer were used for comparison purposes. The six-month survival rate was 100% (23/23) in
the levamisole treated group and 95.3% (102/107) in the control group after curative resection (p
greater than 0.5), 100% (23/23) and 90.5% (49/54) after noncurative resection (p less than 0.01),
and 72.5% (8/11) and 33.3% (9/24), respectively, in non-resectable patients (p less than 0.01). The
one-year survival rate was 100% (21/21) and 95.3% (102/107) after curative resection (p greater
than 0.5), 77.8% (14/18) and 59.3% (32/54) after noncurative resection (0.05 less than p less than
0.1), and 40% (2/5) and 8.3% (2/24) in non-resectable patients (0.05 less than p than 0.1) in the
levamisole group and in the control group, respectively. The difference in survival in survival rates
between levamisole-treated and control groups was most prominent in the non-resectable patients
followed by those undergoing noncurative resection and curative resection.
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Abstract. Levamisole, an agent acting upon depressed cellular im-
munity, enhancing and normalizing it and consequently showing anti-
tumor activity in the cancer-bearing body, was administered to patients
with gastrointestinal cancer at a daily dose of 150 mg for three consecu-
tive days every other week, starting as a rule, three days before opera-
tion. The patients were evaluated for survival. Of the 143 patients (66
with curative resection, 40 with noncurative resection and 37 without
resection) who received levamisole therapy for one month or more, 57
survived postoperatively six months and of 44 treated 37 survived one
year. In this study, 185 patients with gastrointestmal cancer were used
for comparison purposes. The six-month survival rate was 100% (23/23)
in the levamisole treated group and 95.3% (102/107) in the control group
after curative resection (p>0.5), 100% (23/2:::1) and 90.5% (49/54) after
noncurative resection (p<O.01), and 72.5% (8/11) and 33.3% (9/24), res-
pectively, in non-resectable patients (p<O.Ol). The one-year survival
rate was 100% (21/21) and 95.3% (102/107) after curative resection (p>
0.5), 77.8% (14/18) and 59.3% (32/54) after noncurative resection (0.05<
p<O.lj, and 40% (2/5) and 8.3% (2/24) in non-resectable patients (0.05<
p<O.l) in the levamisole group and in the control group, respectively.
The difference in survival rates between levamisole-treated and control
groups was most prominent in the non-resectable patients followed by
those undergoing noncurative resection and curative resection.
Key words: levamisole, gastrointestinal cancer, survival rate,
immunotherapy
Since Mathe et at. (1) used Bacillus Calmette-Guerin (BCG) in the treat-
ment of leukemia, cancer immunotherapy with various immunostimulants has
been practiced widely and the clinical results have been generally encouraging
(2). We studied how cellular immunity of gastrointestinal cancer patients re-
sponded to levamisole which was considered, unlike classic immunostimulants,
to selectively act upon depressed cellular immunity, activate and normalize it (3),
and we reported the ability of levamisole to activate and normalize depressed
cellular immunity (4, 5).
Patients, most of them suffering from gastrointestinal cancer, have been
treated with levamisole at the dosages shown in Table I, and the clinical course
was observed for a year and a half at the longest, with the aim of obtaining
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TABLE 1. CANCER IMMUNOTHERAPY WITH LEVAMISOLE
Chemical formula of levamisole: L-2, 3, 5, 6,-tetrahydro-6-phenylimidazo (2, l-bJ thiazole
hydrochloride
Purpose for this study: Activity of cellular immunity and enhancement of antitumor
activity in cancer patients by levamisole
Method of administration: 150 mg of levamisole daily for three consecutive days every
other week (3 day's medication and 11 day's withdrawal)
Onset of treatment:
a) Three days before operation
b) After operation
c) Concurrently with anticancer therapy
Combination chemotherapy:
Mitomycin C: 5 courses of 4 mg twice a week
Futraful: 600 to 800 mg/day
Examination:
Routine laboratory examination [hematological value, liver function, serum protein,
etc.}
Immunological tests (lymphocyte blastformation rate against phytohemagglutinin,
incidence of T- and B-cells, macrophage migration inhibition test, lymphocyto-
toxicity test, peripheral lymphocyte count, PPD reaction)
evidence of antitumor activity of levamisole. The treatment was started before
operation in most cases. It is interesting to note that the difference in both six-
month and one-year survival rates between treated and cont~olgroups has been
more remarkable in more advanced cancer patients. This confirms our results
from previous experiments (6).
MATERIALS AND METHODS
Levamisole was administered to a group of 143 patients admitted to our de-
partment mainly for gastrointestinal cancer (6, esophageal cancer; 72, gastric
cancer; 27, colorectal cancer; 27, cancer of other organs). Sixty-six of them
underwent curative resection 40 noncurative resection and 37 were not resectable
(Table 2). Another group serving as control in this study included 185 patients
TABLE 2. PATIENTS RECEIVING LEVAMISOLE FOR ONE MONTH OR MORE
_.--- .._-
Site of cancer Curative Noncurative Non-resection Total
resection resection
Esophagus 1( 1 ) 0(0) 5( 0) 6( 1 )
Stomach 40( 7) 20( 0) 12 ( 1 ) 72( 8)
Colorectum 20( 5) 13 (3 ) 8(3) 41 ( 1 )
Other 5 ( 1 ) 7(0 ) 12 ( 0 ) 24 ( 1 )
Total 66(14) 40( 3) 37( 4) 143 (21)
( ) : Number of patients of over 70 years old
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with gastrointestinal cancer admitted to our department during the period from
1971 to 1975 (107 had curative resection and 54 noncurative resection but 24 were
not resectable). There was no noticeable difference between control and leva-
misole groups in regard to patient's age, surgical intervention and cancer chemo-
therapy combined.
A course of levamisole therapy, consisting of oral administration with a daily
dose of 150 mg for three consecutive days followed by ll-day-withdrawal, was
started, as a rule, three days before operation and repeated as much as possible.
The 143 patients followed this course for at least one month and gave sufficient
clinical data for evaluation.
RESULTS
Six-month survival rate. In the group receiving levamisole, those who sur-
vived six postoperative months were 57; 23 had curative resection, 23 had non-
curative resection and 11 were not resectable. In the control group, there were
185 six-month survivals; 107 had curative resection, 54 had noncurative resec-
tion and 24 were not resectable.
After curative resection, the six-month survival rate was 100% (23 of 23
patients) in the levamisole group, while it was 95.3% (102 of 107 patients) in the
control group. There was no significant difference in survival between these
groups (0.I<p<O.5).
After noncurative resection, the survival rate was significantly higher in the
levamisole group than in the control group at the p<O.OI level, since it was
100 % (23 of 23 patients) in the former and 90.7% (49 of 54 patients) in the
latter.
In nonresectable cases, the survival rate was significantly higher in the
levamisole group than in the control group at the p<O.OI level, since it was
72.7% (8 of 11 patients) in the former and 37.5% (9 of 24 patients) in the latter.
The difference in survival between the two groups was much more remarkable in
nonresectable cases than in noncurative cases. It should be noted that no death
occurred during the first five months after operation in levamisole treated pati-
ents.
The elevation of survial rate by levamisole was remarkable in advanced
cancer patients (Fig. 1).
The average survival of the levamisole group and of the control group fol-
lowed up for 6 months were 6 and 5.9 months after curative resection, 6 and 5.7
months after noncurative resection and 5.7 and 3.6 months in nonresectable pa-
tients, respectively.
One-year survival rate. Of the 143 patients who received levamisole, 44
were treated for one year and 37 survived, and in the control group of 185, 136
survived. A comparison was made between the survival rate of levamisole-
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Fig. 1. Six-month Survival Ratios in Gastrointestinal Cancer. --, levamisole
group; ...... , control group; A, curative resection cases in levamisole group,
(23/23), 100%; A': curative resection cases in control group, (102/107), 95.3%
(p>0.5); B: noncurative resection cases in levamisole group, (23/23), 100%; B':
noncurative resection cases in control group, (49/54), 90.7% (p<O.Ol); C: non-re-
section cases in levamisole group, (8/11), 72.7%; C': non-resection cases in control








































Fig. 2. One-year Survival Ratios in Gastrointestinal Cancer. Figure signatures
are the same as Figure 1. A: (21/21),100%; N: (102/107),95.3% (p>0.5); B: (14/18),
77.8%; B': (32/54), 59.3% (0.05<p<O.l); C: (2/5), 40.0%; C': (2/24), 8.3% (0.05<p
<0.1).
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treated patients and that of control patients. After curative resection, 21 patients
receiving levamisole all survived one year, while 102 of 107 patients (95.3 %)
survived for one year in the control group (p>0.5). After noncurative resection,
the one-year survival rate was 77.8% (14 of 18 patients) in the levamisole group
and 59.3% (32 of 54 patients) in the control group (0.05<p<O.I), while in
nonresectable patients, 40% (2 of 5 patients) and 8.3% (2 of 24 patients) (0.05<
p<O.I), respectively. The trend that levamisole was more effective in advanced
and malignant patients was also seen in one-year survival rates. However, the
small number of cases does not permit meaningful statistical examination (Fig. 2).
The average survival of the levamisole group and of the control group
followed for one year were 12 and 11.6 months after curative resection, 10.9 and
9.9 months after noncurative resection and 8.2 and 4.8 months in nonresectable
patients, respective1y.
DISCUSSION
Renoux, G. and Renoux, M. first found that levamisole had antitumor prop-
erties and the ability to enhance cellular immunity (7, 8). A considerable
number of publications regarding levamisole have followed them. As we have
described elsewhere (4, 5), the ability of levamisole to enhance cellular immunity
is characterized, unlike other immunostimulants, by its effect on depressed
cellular immunity alone, enhancing and normalizing it.
The first report dealing with antitumor activity of levamisolein animals
was that of Renoux, G. and Renoux, M. in which levamisole was proved to be
effective against Lewis lung (3LL) tumor in mice (8). However, data on its
effectiveness are controversial; against tumor, levamisole was effective when
administrated by itself (9), effective only when it was used in combination with
anticancer agents (10), or ineffective (11). We started levamisole therapy in mice
when spontaneous breast cancer became palpable. The therapy consisted of 10
subcutaneous doses of 1.15 mg/kg/day administered every other day. Cancer-
bearing mice receiving physiological saline were used for comparison purposes.
It was comfirmed that levamisole had a remarkable antitumor activity and pro-
longed the length of survival time to a considerable extent; the mean survival
was 30 ± 7 days in the control group and 50 ± 10 days in the treated group. Mice
bearing transplanted with hepatoma MH 134 cells were injected with either 10
doses of levamisole 1.15 mg/kg/day dissolved in physiological saline or only
physiological saline, every other day from 7 or 10 days after the tumor transplan-
tation. The animals were evaluated for tumor growth and survival. Levamisole
administered from 10 days after tumor transplantation was found to be most
effective in depressing tumors and prolonging survival (6). This compares
closely with our present findings that the antitumor activity of levamisole is more
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remarkable in more advanced cancers.
Rojas, et al. (12) studied the effect of levamisole in patients with inoperable
Stage III breast cancer who had been treated with radiotherapy alone. The
patients were split into two groups, one assigned to levamisole at 150 mg/day for
three consecutive days every other week and the other not. As a result, the
levamisole-treated patients were protected from recurrence of cancer and be-
nefited by a prolonged survival. Amery (13) performed a double-blind trial with
levamisole on patients with operable bronchogenic cancer. The patients were
allocated to receive levamisole l50mg/kg or a placebo for three consecutive
days every other week from three days before operation. Levamisole-treated
patients had much longer disease-free interval and lower incidence of recurrence
when compared to placebo-treated patients. He also noted that the larger the
tumors were, the more remarkable the antitumor activity of levamisole was (14).
Renoux, G. and Renoux, M. (15) recently reported on 56 patients with advanced
solid tumor which was beyond the control of every available therapy. Fifteen of
them were treated with levamisole and 25 were not. The length of survival time
was remarkably increased in the former 15 patients. Devois (16) administered
levamisole to patients with cancer of various types and obtained a high 25-month
survival rate as compared to those who did not receive levamisole. According to
Devois, 68% of the patients not receiving levamisole therapy were living after
12 months, but it was only after 20 months that the number surviving decreased
to that percentage in levamisole-treated patients. Thus levamisole prolonged the
survival time to a remarkable extent. He also followed up survival for 24 months
in levamisole-treated and untreated patients who were in different stage of breast
cancer. The increase in survival rate due to levamisole was most significant in
Stage IV patients.
These leports are consistent with our results. But some authors disagree
with us. Lichtenfeld et ai. (17), for example, gave levamisole to 23 inoperable
or recurrent lung cancer patients for 35 days but obtained neither prolongation of
survival nor objective improvement.
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